Microwave Ablation of Lung Malignancies: Effectiveness, CT Findings, and Safety in 50 Patients
Authors:
- David J. GrandDGDavid J. Grand
- Jason T. MachanJMJason T. Machan
- Thomas A. DiPetrilloTDThomas A. DiPetrillo
- William W. Mayo-SmithWMWilliam W. Mayo-Smith
- Damian E. DupuyDDDamian E. Dupuy
- 1 June 2008
- journal article
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 247 (3) , 871-879
Abstract
To retrospectively evaluate effectiveness, follow-up imaging features, and safety of microwave ablation in 50 patients with intraparenchymal pulmonary malignancies. This HIPAA-compliant study was approved by the institutional review board; informed consent was waived. From November 10, 2003, to August 28, 2006, 82 masses (mean, 1.42 per patient) in 50 patients (28 men, 22 women; mean age, 70 years) were percutaneously treated in 66 microwave ablation sessions. Each tumor was ablated with computed tomographic (CT) guidance. Follow-up contrast material-enhanced CT and positron emission tomographic (PET) scans were reviewed. Mixed linear modeling and logistic regression were performed. Time-event data were analyzed (Kaplan-Meier survival estimates and log-rank statistic). All event times were the time to a patient's first event (alpha level = .05, all analyses). At follow-up (mean, 10 months), 26% (13 of 50) of patients had residual disease at the ablation site, predicted by using index size of larger than 3 cm (P = .01). Another 22% (11 of 50) of patients had recurrent disease resulting in a 1-year local control rate of 67%, with mean time to first recurrence of 16.2 months. Kaplan-Meier analysis yielded an actuarial survival of 65% at 1 year, 55% at 2 years, and 45% at 3 years from ablation. Cancer-specific mortality yielded a 1-year survival of 83%, a 2-year survival of 73%, and a 3-year survival of 61%; these values were not significantly affected by index size of larger than 3 cm or 3 cm or smaller or presence of residual disease. Cavitation (43% [35 of 82] of treated tumors) was associated with reduced cancer-specific mortality (P = .02). Immediate complications included pneumothorax (Common Terminology Criteria for Adverse Events [CTCAE] grades 1 [18 of 66 patients] and 2 [eight of 66 patients]), hemoptysis (four of 66 patients), and skin burns (CTCAE grades 2 [one of 66 patients] and 3 [one of 66 patients]). Microwave ablation is effective and may be safely applied to lung tumors. (c) RSNA, 2008.Keywords
This publication has 24 references indexed in Scilit:
- CT Imaging Findings of Pulmonary Neoplasms After Treatment with Radiofrequency Ablation: Results in 32 TumorsAmerican Journal of Roentgenology, 2005
- Image-guided Tumor Ablation: Standardization of Terminology and Reporting CriteriaJournal of Vascular and Interventional Radiology, 2005
- Percutaneous Image-Guided Radiofrequency Ablation of Painful Metastases Involving Bone: A Multicenter StudyJournal of Clinical Oncology, 2004
- Imaging-Guided Percutaneous Radiofrequency Ablation of Solid Renal Masses: Techniques and Outcomes of 38 Treatment Sessions in 32 Consecutive PatientsAmerican Journal of Roentgenology, 2003
- Renal Cell Carcinoma: Clinical Experience and Technical Success with Radio-frequency Ablation of 42 TumorsRadiology, 2003
- Phantom and animal tissues for modelling the electrical properties of human liverInternational Journal of Hyperthermia, 2003
- Percutaneous Radio-frequency Ablation of Hepatic Metastases from Colorectal Cancer: Long-term Results in 117 PatientsRadiology, 2001
- Hepatocellular Carcinoma: Radio-frequency Ablation of Medium and Large LesionsRadiology, 2000
- A theoretical comparison of energy sources - microwave, ultrasound and laser - for interstitial thermal therapyPhysics in Medicine & Biology, 1998
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958